A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 15 May 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Etoposide; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel; Paclitaxel
- Indications Breast cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 11 May 2017 Planned End Date changed from 29 May 2018 to 1 Jul 2019.
- 11 May 2017 Planned primary completion date changed from 29 May 2018 to 1 Jul 2019.
- 06 Apr 2017 Status changed from active, no longer recruiting to recruiting.